- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05918198
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Clinical Study of BCL-2 Inhibitor Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Study Overview
Detailed Description
The main questions it aims to answer are:
- Safety of Ven combined with CAG regimen in the treatment of relapsed/refractory AML patients
- Efficacy of Ven combined with CAG regimen in the treatment of relapsed/refractory AML patients Participants will receive therapy of venetoclax and CAG regimen (Ara-C, Acla and C C-GSF)
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wen-Jing Yu, M.D.
- Phone Number: 18813187365
- Email: yuwenjing789@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital
-
Contact:
- Wen-Jing Yu
- Phone Number: 18813187365
- Email: yuwenjing789@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years ≤ age ≤ 75 years, male and female are not limited.
- According to bone marrow morphology and immunophenotype, it was diagnosed as acute myeloid leukemia ( WHO 2016 diagnostic criteria).
- Morphological recurrence after complete remission (CR) (leukemic cells in the peripheral blood of CR patients or more than 5% of the blasts in the bone marrow or new pathological hematopoiesis or extramedullary leukemic cell infiltration) or acute myeloid leukemia patients who did not achieved CR after 1 cycle of chemotherapy.
- The ECOG (Eastern Cancer Cooperation Group of the United States) PS score is 0-1.
- The expected survival time is ≥ 12 weeks.
- Female patients of childbearing age need to undergo pregnancy examination before receiving chemotherapy, and must agree to take effective contraceptive measures during treatment.
- Subjects volunteered to participate, fully informed consent, signed an informed consent, and good compliance.
Exclusion Criteria:
- Other malignant hematological diseases that do not conform to the diagnosis of acute myeloid leukemia.
- Allergy to any drugs involved in the project.
- History of serious cardiovascular and cerebrovascular diseases: ① Congestive heart failure, unstable angina pectoris, myocardial infarction, stroke or poorly controlled arrhythmia with NYHA grade II or above occurred within 12 months before enrollment,LVEF (left ventricular ejection fraction)<50% by color Doppler ultrasound,Corrected QT interval (QTc)>480ms (calculated by Fridericia method, if the QTc is abnormal, it can be detected continuously for 3 times every 2 minutes, and the average value is taken),Hypertension difficult to control by drugs (systolic blood pressure (BP) ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg) (based on the average of ≥ 3 BP readings obtained from ≥ 2 measurements),Have had hypertensive crisis or hypertensive encephalopathy in the past.
- There are other obvious bleeding tendencies or evidence of major coagulation disorders: ①Hemoptysis of any reason occurred within 2 weeks before enrollment,② Thrombosis or embolism occurred within 6 months before enrollment,③ Anticoagulant therapy for therapeutic purposes (except low molecular weight heparin therapy) be used within 2 weeks before enrollment④ Antiplatelet therapy is required.
- Abnormal liver function: total bilirubin>3 mg/dL;Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 × Upper limit of normal value (ULN).
- Abnormal renal function: serum creatinine ≥ 1.5 × ULN, or the creatinine clearance rate (CrCl) calculated according to Cockroft-Gault formula is less than 60 mL/min (if the calculated CrCl is less than 60 mL/min, the researcher may ask to confirm the 24-hour CrCl, in this case, the subjects with 24-hour CrCl less than 60 mL/min should be excluded).
- Other serious diseases that may limit the patient's participation in this clinical trial (including but not limited to other malignant tumors, active infection, serious uncured wounds, active ulcers and untreated fractures, history of human immunodeficiency virus infection, and receiving allogeneic stem cells or solid organ transplantation).
- Cannot swallow pills, malabsorption syndrome or any condition that affects gastrointestinal absorption.
- Other clinical trials are being conducted.
- Unable to understand or cooperate to complete the research protocol.
- Pregnant and lactating patients
- Other situations that the researcher believes are not suitable for inclusion in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ven+CAG
Venetoclax plus CAG regimen
|
100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day. Ara-C 10mg/m2, ih, q12h × 14d; Acla 20mg/d × 4d; G-CSF 5ug/kg × 14d (WBC > 30 × 10^9/L pause)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CR/CRi rate
Time Frame: 2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
the rate of complete remission or complete remission with incomplete hematologic recovery
|
2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
CR/CRi rate
Time Frame: 2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
the rate of complete remission or complete remission with incomplete hematologic recovery
|
2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD status
Time Frame: 2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
MRD-positive status was defined as FCM positivity in two consecutive BM samples at a 2-week interval, PCR positivity in two consecutive BM samples at a 2-week interval, or both FCM and PCR positivity in a single BM sample after the first-month post-HSCT.
Positive FCM was defined as >0.01% of cells with a LAIPs phenotype in >1 BM samples after transplantation.
The expressions of leukemia-associated genes were evaluated by TaqMan-based RT-PCR, including Wilms' tumor gene 1 (WT1) and genes which were determined in the diagnostic specimens.
|
2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
MRD status
Time Frame: 2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
MRD-positive status was defined as FCM positivity in two consecutive BM samples at a 2-week interval, PCR positivity in two consecutive BM samples at a 2-week interval, or both FCM and PCR positivity in a single BM sample after the first-month post-HSCT.
Positive FCM was defined as >0.01% of cells with a LAIPs phenotype in >1 BM samples after transplantation.
The expressions of leukemia-associated genes were evaluated by TaqMan-based RT-PCR, including Wilms' tumor gene 1 (WT1) and genes which were determined in the diagnostic specimens.
|
2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
objective remission rate(ORR)
Time Frame: 2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
The percentage of people in a study or treatment group who have a partial response or complete response to the treatment within a certain period of time.
|
2 to 3 weeks after the end of cycle 1 (each cycle is 14 days)
|
objective remission rate(ORR)
Time Frame: 2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
The percentage of people in a study or treatment group who have a partial response or complete response to the treatment within a certain period of time.
|
2 to 3 weeks after the end of cycle 2 (each cycle is 14 days)
|
Progression-free survival (PFS)
Time Frame: Throughout the whole research process, assessed up to 24 months
|
From date of Ven plus CAG therapy beginning until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Throughout the whole research process, assessed up to 24 months
|
Overall survival
Time Frame: Throughout the whole research process, assessed up to 24 months
|
From date of Ven plus CAG therapy beginning until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Throughout the whole research process, assessed up to 24 months
|
The incidence of adverse events
Time Frame: Throughout the whole research process, assessed up to 24 months
|
According to Common Terminology Criteria for Adverse Events, CTCAE, V5.0, assessed up to 24 months
|
Throughout the whole research process, assessed up to 24 months
|
Collaborators and Investigators
Investigators
- Study Chair: Wen-Jing Yu, M.D., Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RDL2022-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Ven+CAG
-
Applied Biology, Inc.Hospital Universitario Ramon y CajalWithdrawnCOVID-19 | SARS-CoV 2 | COVID | Androgenetic Alopecia | Androgen Deficiency | Androgen Receptor AbnormalSpain
-
Aarhus University Hospital SkejbyOdense University Hospital; Rigshospitalet, Denmark; Aalborg University HospitalRecruitingPercutaneous Coronary Intervention | Coma | Cardiac Arrest, Out-Of-Hospital | AngiographyDenmark
-
Mental Health Services in the Capital Region, DenmarkMaria Faurholt-Jepsen, MD, DMSc; The Mental Health Services in the Capital...Recruiting
-
Harbin Medical UniversityRecruitingCoronary Artery Disease Acute Coronary Syndrome Myocardial Ischemia Plaque CharacterizationChina
-
Dong-A UniversityUnknown
-
Ruijin HospitalMed-X Research Institute, Shanghai Jiao Tong UniversityRecruitingPrimary Valvular Heart Disease With Comorbid Coronary Artery Disease | Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart DiseaseChina
-
Shanghai Jiao Tong University School of MedicineRecruitingRefractory Acute Myeloid LeukemiaChina
-
The Second Affiliated Hospital of Kunming Medical...Guizhou Provincial People's Hospital; Central South University; First Affiliated... and other collaboratorsNot yet recruitingAcute Myeloid Leukemia, AdultChina
-
Kahramanmaras Sutcu Imam UniversityUnknown
-
Janssen Research & Development, LLCActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited Kingdom, France, Korea, Republic of, Spain